| Title |
Mirtazapine
|
|---|---|
| Published in |
CNS Drugs, August 2012
|
| DOI | 10.2165/00023210-200923050-00006 |
| Pubmed ID | |
| Authors |
Katherine F. Croom, Caroline M. Perry, Greg L. Plosker |
| Abstract |
Mirtazapine (Remeron, Zispin) is a noradrenergic and specific serotonergic antidepressant (NaSSA) that is approved in many counties for use in the treatment of major depression. Monotherapy with mirtazapine 15-45 mg/day leads to rapid and sustained improvements in depressive symptoms in patients with major depression, including the elderly. It is as effective as other antidepressants and may have a more rapid onset of action than selective serotonin reuptake inhibitors (SSRIs). Furthermore, it may also have a higher sustained remission rate than amitriptyline. Preliminary data suggest that mirtazapine may also be effective in the treatment of anxiety disorders (including post-traumatic stress disorder, panic disorder and social anxiety disorder), obsessive-compulsive disorder, undifferentiated somatoform disorder and, as add-on therapy, in schizophrenia, although large, well designed trials are needed to confirm these findings. Mirtazapine is generally well tolerated in patients with depression. In conclusion, mirtazapine is an effective antidepressant for the treatment of major depression and also has the potential to be of use in other psychiatric indications. |
Mendeley readers
The data shown below were compiled from readership statistics for 213 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 1 | <1% |
| Canada | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 210 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 30 | 14% |
| Student > Master | 27 | 13% |
| Student > Bachelor | 22 | 10% |
| Student > Ph. D. Student | 19 | 9% |
| Student > Doctoral Student | 16 | 8% |
| Other | 37 | 17% |
| Unknown | 62 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 56 | 26% |
| Psychology | 29 | 14% |
| Nursing and Health Professions | 11 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 5% |
| Neuroscience | 7 | 3% |
| Other | 28 | 13% |
| Unknown | 72 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 January 2023.
All research outputs
#3,415,510
of 25,374,917 outputs
Outputs from CNS Drugs
#292
of 1,388 outputs
Outputs of similar age
#23,530
of 187,955 outputs
Outputs of similar age from CNS Drugs
#92
of 541 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,388 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.6. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 187,955 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 541 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.